ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• Enzon Pharmaceuticals (ENZN) filed an 8‑K on Feb 27, 2026 reporting the Eighth Amendment to its Section 382 Rights Agreement (originally dated Aug 14, 2020). The Eighth Amendment, entered into Feb 27, 2026, moves the Rights Agreement’s Final Expiration Date from noon (New York City time) on March 2, 2026 to noon (New York City time) on March 11, 2026. The Rights Agreement is otherwise unchanged.
• The company also issued a press release saying it extended the expiration for its exchange offer (to exchange Series C Non‑Convertible Redeemable Preferred Stock for common stock). After the extension the Offer now expires one minute after 11:59 p.m. Eastern time on March 9, 2026, unless further extended.

Key Details

• Eighth Amendment signed: February 27, 2026.
• New Rights Agreement Final Expiration Date: noon, New York City time, March 11, 2026 (was noon on March 2, 2026).
• Exchange offer (Series C Preferred → common stock) expiry: one minute after 11:59 p.m. ET on March 9, 2026.
• Rights Agreement originally filed Aug 14, 2020; multiple prior amendments extended expiration dates before this latest amendment. No other changes to the Rights Agreement.

Why It Matters

• The extension preserves the shareholder protections and timing associated with the Section 382 Rights Agreement for an additional period and gives holders more time to decide on the Series C exchange offer.
• For investors, the filing is procedural but material: it affects the timeline for the exchange offer and is connected to Enzon’s ongoing disclosure around a proposed transaction with Viskase (a Form S‑4 was filed). Investors tracking the merger, the exchange of Series C preferred shares, or potential ownership/timing impacts should note the new deadlines.